Hearing Loss Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies by DelveInsight
DelveInsight's, 'Hearing Loss Pipeline Insight' report provides comprehensive insights about 32+ companies and 35+ pipeline drugs in Hearing Loss pipeline landscape. It covers the Hearing Loss pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Hearing Loss therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Stay ahead with the latest insights! Download DelveInsight's comprehensive Hearing Loss Pipeline Report to explore emerging therapies, key Hearing Loss Companies, and future Hearing Loss treatment landscapes @ Hearing Loss Pipeline Outlook Report
Key Takeaways from the Hearing Loss Pipeline Report
In January 2025:- AudioCure Pharma GmbH- The purpose of this Phase 2 clinical trial is to evaluate the safety, tolerability and efficacy of AC102 administered as single intratympanic injection compared to oral steroid treatment in patients with Idiopathic Sudden Sensorineural Hearing Loss (ISSNHL).
In January 2025:- Laboratoires Thea:- The purpose of this Phase 2b study is to evaluate the safety and tolerability of Ultevursen administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene. This is a multicenter Double-masked, Randomized, Sham-controlled study which will enroll 81 subjects.
In January 2025:- Akouos Inc.:- This trial will evaluate the safety and tolerability of a single unilateral administration of one of three dose levels of AAVAnc80-antiVEGF and will evaluate the Akouos delivery device to safely achieve the intended product performance.
DelveInsight's Hearing Loss pipeline report depicts a robust space with 32+ active players working to develop 35+ pipeline therapies for Hearing Loss treatment.
The leading Hearing Loss Companies such as Acousia Therapeutics, Decibel Therapeutics, Otonomy Inc., Sensorion, Autifony Therapeutics, Auris Medical, Sound Pharmaceuticals, Anida Pharma Inc., Gateway Biotechnology, Myrtelle Inc., Lineage Cell Therapeutics, Inc., Altamira Therapeutics, Hoba Therapeutics, Rinri Therapeutics, Autifony Therapeutics, Otologic Pharmaceutics, Audion Therapeutics, Perha Pharmaceuticals, Applied Genetic Technologies Corporation, Akouos, Inc., Oricula Therapeutics, Spiral Therapeutics, Pipeline Therapeutics, Prime Medicine, Boehringer Ingelheim, Autigen, Heyu (Suzhou) Pharmaceutical Technology Co., Ltd, Astellas Pharma, Mogrify Limited and others.
Promising Hearing Loss Therapies such as AM-111, FX-322, AUT00063, FX-322 (One Dose), AC102 Gel, Prednisolone, OTO-413, andothers.
Discover how the Hearing Loss treatment paradigm is evolving. Access DelveInsight's in-depth Hearing Loss Pipeline Analysis for a closer look at promising breakthroughs @ Hearing Loss Clinical Trials and Studies
Hearing Loss Emerging Drugs Profile
SENS-401: Sensorion
SENS-401 (Arazasetron), Sensorion's clinical stage lead drug candidate, is an orally available small molecule that aims to protect and preserve inner ear tissue from damage responsible of progressive or sequelae hearing impairment. Sensorion is currently developing SENS-401 in a Phase IIa clinical trial for the prevention of residual hearing loss in patients scheduled for cochlear implantation, and in a Phase II clinical trial for the prevention of Cisplatin-Induced Ototoxicity. SENS-401 has been granted Orphan Drug Designation by the EMA in Europe for the treatment of sudden sensorineural hearing loss, and by the FDA in the US for the prevention of platinum-induced ototoxicity in pediatric population. It is currently being evaluated in Phase II/III stage of development.
ACOU085: Acousia Therapeutics
ACOU085 is a proprietary small-molecule drug candidate under clinical development, with a particular focus on its use as an etiology-agnostic otoprotectant for patients with acute forms of sensorineural hearing loss. The company has successful completed Phase Ib study, following the final visit of the last patient treated with the highest ACOU085 dose. The next step is a clinical Phase II study using ACOU085 to protect the inner ears of testicular cancer patients undergoing chemotherapy from cisplatin-induced ototoxicity. It will be initiated in early 2023.
OTO-413: Otonomy Inc.
OTO-413 is a proprietary, sustained-exposure formulation of brain-derived neurotrophic factor (BDNF), which is a naturally occurring protein involved in neuron growth and repair. Nonclinical studies have demonstrated that local administration of BDNF repairs the connections between inner hair cells and auditory nerve fibers in the cochlea that are damaged due to noise trauma or exposure to ototoxic chemicals. Furthermore, Otonomy has demonstrated in preclinical studies that repair of synaptic connections is associated with a restoration of hearing function. Initial clinical studies have demonstrated that a single intratympanic injection of OTO-413 is well-tolerated and improves hearing function across multiple clinically validated speech-in-noise hearing tests. Currently, the drug is being evaluated in the Phase I/II stage of development.
DB-020: Decibel Therapeutics
DB-020 is a proprietary formulation of sodium thiosulfate (STS) optimized for local delivery to the ear and is being investigated for its potential to protect against cisplatin-induced hearing loss without impacting the beneficial effect of cisplatin. DB-020 is designed to achieve high cochlear concentrations of STS following a local injection through the ear drum, or transtympanically, into the middle ear. Transtympanic injection is a brief, minimally invasive, routine, office-based procedure performed by ENTs and is generally well-tolerated. A randomized, double-blind, placebo-controlled Phase I clinical trial of DB-020 in normal healthy volunteers was completed in 2019. A randomized, double-blind, placebo-controlled, multicenter Phase Ib clinical trial of DB-020 in patients undergoing treatment with cisplatin is ongoing. DB-020 has been granted Fast Track designation by the US Food and Drug Administration (FDA). DB-020 is an investigational therapy for the prevention of cisplatin-induced hearing loss, a serious and debilitating condition for which there are no currently approved therapies. Currently, the drug is in the Phase I stage of development.
Hearing Loss Companies
Acousia Therapeutics, Decibel Therapeutics, Otonomy Inc., Sensorion, Autifony Therapeutics, Auris Medical, Sound Pharmaceuticals, Anida Pharma Inc., Gateway Biotechnology, Myrtelle Inc., Lineage Cell Therapeutics, Inc., Altamira Therapeutics, Hoba Therapeutics, Rinri Therapeutics, Autifony Therapeutics, Otologic Pharmaceutics, Audion Therapeutics, Perha Pharmaceuticals, Applied Genetic Technologies Corporation, Akouos, Inc., Oricula Therapeutics, Spiral Therapeutics, Pipeline Therapeutics, Prime Medicine, Boehringer Ingelheim, Autigen, Heyu (Suzhou) Pharmaceutical Technology Co., Ltd, Astellas Pharma, Mogrify Limited and others.
Hearing Loss pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
Oral
Intravenous
Subcutaneous
Parenteral
Topical
Hearing Loss Products have been categorized under various Molecule types such as
Recombinant fusion proteins
Small molecule
Monoclonal antibody
Peptide
Polymer
Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming therapies and key developments @ Hearing Loss Market Drivers and Barriers, and Future Perspectives
Scope of the Hearing Loss Pipeline Report
Coverage- Global
Hearing Loss Companies- Acousia Therapeutics, Decibel Therapeutics, Otonomy Inc., Sensorion, Autifony Therapeutics, Auris Medical, Sound Pharmaceuticals, Anida Pharma Inc., Gateway Biotechnology, Myrtelle Inc., Lineage Cell Therapeutics, Inc., Altamira Therapeutics, Hoba Therapeutics, Rinri Therapeutics, Autifony Therapeutics, Otologic Pharmaceutics, Audion Therapeutics, Perha Pharmaceuticals, Applied Genetic Technologies Corporation, Akouos, Inc., Oricula Therapeutics, Spiral Therapeutics, Pipeline Therapeutics, Prime Medicine, Boehringer Ingelheim, Autigen, Heyu (Suzhou) Pharmaceutical Technology Co., Ltd, Astellas Pharma, Mogrify Limited and others.
Hearing Loss Therapies- AM-111, FX-322, AUT00063, FX-322 (One Dose), AC102 Gel, Prednisolone, OTO-413, andothers.
Hearing Loss Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
Hearing Loss Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Which companies are leading the race in Hearing Loss drug development? Find out in DelveInsight's exclusive Hearing Loss Pipeline Report—access it now! @ Hearing Loss Emerging Drugs and Major Companies
Table of Content
Introduction
Executive Summary
Hearing Loss: Overview
Pipeline Therapeutics
Therapeutic Assessment
Hearing Loss– DelveInsight's Analytical Perspective
Mid Stage Products (Phase II/III)
SENS-401: Sensorion
Drug profiles in the detailed report…..
Early Stage Products (Phase I/II)
OTO-413: Otonomy Inc.
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
ACOU085: Acousia Therapeutics
Drug profiles in the detailed report…..
Preclinical and Discovery Stage Products
Research programme: Hearing Loss: Autifony Therapeutics
Drug profiles in the detailed report…..
Inactive Products
Hearing Loss- Unmet Needs
Hearing Loss- Market Drivers and Barriers
Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9650213330
Address: 304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/report-store/catheter-stabilization-securement-device-market
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
2 days ago
- Globe and Mail
Financial lessons from a woman whose husband died suddenly at 39
If you can't find the time or motivation to plan financially for your death or a serious illness, please read Jane Blaufus's book. It's called With the Stroke of a Pen: Claim Your Life, and it includes a 33-page checklist of questions for working through the process of helping family members sort through your affairs when you die. The checklist is helpful, but so is Ms. Blaufus's personal experience after the loss of her husband. To hear more, check out this e-mail Q&A I did with Ms. Blaufus: Q: Jane, can you tell us in both a personal and professional sense how you came to write your book? A: My 39-year-old husband walked out the door one Sunday morning, and that afternoon a police officer arrived in my driveway to share the news that he had been killed in an accident. In less than 60 seconds, the world I knew had been turned upside down and I had become a widow with a 12-year-old daughter and a financial tsunami coming my way. By that time, I had been in the life insurance industry for 16 years and had foolishly thought that if anything ever happened to me that I would be better prepared than others. Wrong. I was blindsided by so many unexpected things and thought that if I wasn't prepared, despite all of my knowledge and expertise, what would the average person do in that situation? Fast forward to today and I am happily remarried to a wonderful man who was also widowed after his wife suffered an illness. We collectively decided to pay it forward by sharing our story to help prevent other families from going through what we did. Q: In the conversations you've had with readers, friends, family and clients in your professional life, what have you learned about the capacity people have for preparing for their own death and the death of loved ones? Do we ever get to a point where nine in 10 people have a will, powers of attorney and made other preparations? A: Unfortunately, most people are terrified to talk about death and illness. For many it is like looking their own mortality in the face, but these conversations are crucial because we have an obligation to ourselves and those we love to leave this world in an organized manner. The last thing someone needs when a loved one has become ill or died is to be running around trying to find all the pertinent documents needed to make decisions about medical care or funeral arrangements. Sadly, I do not think we will ever get to the point where nine in ten people will have had these important conversations. Q: If you were to list some of the top things to do to make sure your loved ones are prepared in case of your death, what would they be? A: To start, make sure your loved ones know what your final wishes are. I had asked my husband four times what he would want if anything happened to him and he would always change the subject. When he died, I had to plan a funeral as if I had been blindfolded; it was horrible. Next, make sure you have a current, up-to-date will and powers of attorney for both medical and financial matters. You would not believe the number of times I have heard stories about couples divorcing and the ex-spouse gets everything because the will was never changed. Also, make sure you have enough life insurance for today. Do not stick your policy in a drawer, as things have a way of changing over time. Also, if you have a special needs member of the family, make sure you have provided for them to be cared for in the future. Please make sure all of the beneficiary designations are correct and current as well. And, make sure you have assembled all of your important documentation into one central location, and make sure everyone who should know where it is, does. Your loved ones and your executor should be able to quickly and easily access this information. Speaking of executors, make sure you have asked your executor and legal guardians for your underage children if they willingly accept the role and associated responsibilities. Do not simply assume they will, because if they decline to accept the role after you are gone, you cannot make changes from the grave. Q: What do you think about bringing your adult children into the discussion of what happens when you die? How old should kids be for this conversation? A: This is a very important question, and I believe it is critical to bring them into the discussion, especially today, where there are so many blended families. Having them involved in the conversation can mitigate so many issues that have the potential to erupt after someone dies. As for your question about how old they should be, I would leave this in the parents' hands to determine the age, as they will know their child's maturity level better than anyone else. However, at the latest, I personally would bring them in when they reach adulthood. My poor daughter has had more of these conversations than I think she would care for! Q: Looking back on your own experience when your husband died, what types of advance planning had you done and how did they help in the aftermath? A: The year before my husband died, we had met with our financial advisor to review our investments and life insurance policies. We actually purchased more insurance as things had changed from our last review. The life insurance my husband lovingly put in place for us became a financial lifeline that helped me as I tried to get back on my feet and return to work. We also reviewed our wills with our lawyer, which made settling his estate much easier for me. Q: I've seen some apps and software over the years that were designed to help people organize themselves for when they die, but none seems to have taken off. Do you think the right app could help people engage more with this type of planning, and do you know any apps people should check out? A: I personally do not think an app would engage more people and I do not have a go-to suggestion to offer. What I have done in my book is provide my readers with a checklist designed to help get the conversations going with the people you need to be having them with. It serves as a workbook to help people get their personal and financial lives in order while they can. Are you reading this newsletter on the web or did someone forward the e-mail version to you? If so, you can sign up for Carrick on Money here. Dollarama vs. Costco A nine-product price comparison, including staples like tomato sauce and paper towels. Would you buy a Canadian car? How feasible would it be to tap into Buy Canada sentiment by launching an actual Canadian car company? Foreign companies assemble vehicles in this country, but there are no Canadian automakers. Fixing the problem of too much stuff Advice on de-cluttering from YouTube's The Minimal Mom. The emphasis is on making your living space more comfortable, not throwing a lot of stuff out. Life with the Cybertruck An amusing take on what it's like to drive the Tesla Cybertruck, which starts around $120,000 in Canada. A recent report from J.D. Power shows that in the segment of people who say they are likely to consider an electric vehicle for their next purchase, Tesla has dropped to eighth place after four years among the top two. Subscribe to Stress Test on Apple Podcasts or Spotify. Ask Rob Q: What should the investing approach for seniors be for stocks versus guaranteed income certificates? One, both, neither? A: Both can work well. Stocks for long-term growth and dividend income, GICs to supplement bonds as a source of interest income and stability when stocks decline. An all-stocks approach is too risky for most seniors, while all GICs means a sacrifice of growth for safety. The 5 per cent GIC yields of a few years ago far exceed today's peak rates of 3.5 to 3.95 per cent. Tools and guides This new retirement planning calculator was created by a team including Ben Felix, a portfolio manager who has done a lot of great educational work. In the social sphere Social Media: A LinkedIn discussion about a column I wrote recently about a proposal to tax real estate investment properties. Watch: Toronto's spring housing market: Dead on arrival Money-Free Zone: The band Wye Oak strips down the Kate Bush song Running Up That Hill to the basics, and makes it work. Here's the great, more ornate original version. More PF from The Globe - They downsized to save money and simplify their lives. Here's what they wished they'd known - For travel-loving Canadians, other financial goals take a back seat to vacation spending - When did tipping diverge from a reward for good service to a wage-subsidization tactic?
Globe and Mail
5 days ago
- Globe and Mail
Chronic Insomnia Market Growth Projections 2023-2032: DelveInsight Analysis
The Key Chronic Insomnia Companies in the market include - Janssen Research & Development, Takeda, and others. The Chronic Insomnia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Insomnia pipeline products will significantly revolutionize the Chronic Insomnia market dynamics. DelveInsight's 'Chronic Insomnia Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Chronic Insomnia, historical and forecasted epidemiology as well as the Chronic Insomnia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan. Some of the key facts of the Chronic Insomnia Market Report: The Chronic Insomnia market size was valued ~USD 333 million in 2021 and is anticipated to grow with a significant CAGR during the study period (2019-2032) Among the seven major markets (7MM), the United States represented 67.3% of the total market size for Chronic Insomnia in 2021. In the 7 MM countries, there will be 5,697,127 cases of chronic insomnia that have been diagnosed as of 2021 Age plays a significant role in how the disease develops. The age group of 20 to 29 years saw the highest number of cases in the US in 2021 with 474,746. Following this, there were 421,996 instances in the US for each of the age groups of 30-39 and 40-49 years France had the greatest diagnosed prevalence of chronic insomnia among the European nations, with 890,539 cases. Germany came in second with 407,108 cases in 2021 Germany reported 207,625 instances of chronic insomnia in females and 199,483 cases in men among the EU5 nations in 2021 Key Chronic Insomnia Companies: Janssen Research & Development, Takeda, and others Key Chronic Insomnia Therapies: Seltorexant, Ramelteon and zolpidem, and others The Chronic Insomnia epidemiology based on gender analyzed that Chronic Insomnia is more prominent in females in comparison to males The Chronic Insomnia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Chronic Insomnia pipeline products will significantly revolutionize the Chronic Insomnia market dynamics. Chronic Insomnia Overview Chronic insomnia is a long-term sleep disorder characterized by difficulty falling asleep, staying asleep, or waking up too early, occurring at least three times a week for three months or more. It leads to daytime fatigue, impaired concentration, mood disturbances, and reduced quality of life. Causes can include stress, medical conditions, medications, or poor sleep habits. Get a Free sample for the Chronic Insomnia Market Report: Chronic Insomnia Epidemiology The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends. Chronic Insomnia Epidemiology Segmentation: The Chronic Insomnia market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into: Total Prevalence of Chronic Insomnia Prevalent Cases of Chronic Insomnia by severity Gender-specific Prevalence of Chronic Insomnia Diagnosed Cases of Episodic and Chronic Chronic Insomnia Download the report to understand which factors are driving Chronic Insomnia epidemiology trends @ Chronic Insomnia Epidemiology Forecast Chronic Insomnia Drugs Uptake and Pipeline Development Activities The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Chronic Insomnia market or expected to get launched during the study period. The analysis covers Chronic Insomnia market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share. The report also covers the Chronic Insomnia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies. Chronic Insomnia Therapies and Key Companies Discover more about therapies set to grab major Chronic Insomnia market share @ Chronic Insomnia Treatment Market Chronic Insomnia Market Drivers Increasing Prevalence Personalization of therapies Chronic Insomnia Market Barriers Issues with diagnosis and poor knowledge Use of off-label drugs High economic burden Scope of the Chronic Insomnia Market Report Study Period: 2019–2032 Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan] Key Chronic Insomnia Companies: Janssen Research & Development, Takeda, and others Key Chronic Insomnia Therapies: Seltorexant, Ramelteon and zolpidem, and others Chronic Insomnia Therapeutic Assessment: Chronic Insomnia current marketed and Chronic Insomnia emerging therapies Chronic Insomnia Market Dynamics: Chronic Insomnia market drivers and Chronic Insomnia market barriers Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies Chronic Insomnia Unmet Needs, KOL's views, Analyst's views, Chronic Insomnia Market Access and Reimbursement Table of Contents 1. Chronic Insomnia Market Report Introduction 2. Executive Summary for Chronic Insomnia 3. SWOT analysis of Chronic Insomnia 4. Chronic Insomnia Patient Share (%) Overview at a Glance 5. Chronic Insomnia Market Overview at a Glance 6. Chronic Insomnia Disease Background and Overview 7. Chronic Insomnia Epidemiology and Patient Population 8. Country-Specific Patient Population of Chronic Insomnia 9. Chronic Insomnia Current Treatment and Medical Practices 10. Chronic Insomnia Unmet Needs 11. Chronic Insomnia Emerging Therapies 12. Chronic Insomnia Market Outlook 13. Country-Wise Chronic Insomnia Market Analysis (2019–2032) 14. Chronic Insomnia Market Access and Reimbursement of Therapies 15. Chronic Insomnia Market Drivers 16. Chronic Insomnia Market Barriers 17. Chronic Insomnia Appendix 18. Chronic Insomnia Report Methodology 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight About DelveInsight DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach. Media Contact Company Name: DelveInsight Business Research LLP Contact Person: Gaurav Bora Email: Send Email Phone: +14699457679 Address: 304 S. Jones Blvd #2432 City: Las Vegas State: NV Country: United States Website:
CBC
29-05-2025
- CBC
Popular Shubenacadie Wildlife Park bear dies
Bonnie Bear left behind a brother — Clyde. Meig Campbell has an update on how he is handling the loss.
